Considerations for new dual-acting bronchodilator treatments for chronic obstructive pulmonary disease

Expert Opinion on Investigational Drugs

Volumn 23, Issue 4, 2014, Pages 453-456

  De Miguel Díez, Javier ^a   Jiménez García, Rodrigo ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Fixed dose combinations; Long acting muscarinic antagonists

Indexed keywords

ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; GLYCOPYRRONIUM BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; OLODATEROL PLUS TIOTROPIUM BROMIDE; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG INDUSTRY; DRUG SAFETY; HUMAN; INHALER; PATIENT COMPLIANCE; PHARMACODYNAMICS; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; HUMANS; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84896117363     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2014.876409     Document Type: Review

References (15)

1. Dahl R, Jadayel D, Alagappan VKT, et al. Efficacy and safety of QVA 149 compared to the concurrents administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis 2013;8:501-8 .
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2013. Available from: http://www.goldcopd.org [Last accessed 21 October 2013]
3. Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther 2013;7:1201-8 .
4. Cazzola M, López-Campos JL, Puente-Maestu L. The MABA approach: a new option to improve bronchodilator therapy. Eur Respir J 2013;42:885-7
5. Norman P. New dual-acting bronchodilator treatments for COPD, muscarinic antagonists and beta2 agonists in combination or combined into a single molecule. Expert Opin Investig Drugs 2013;22:1569-80
6. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013;1:199-209 .
7. Tashkin DP, Ferguson GT. Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res 2013;14:49
8. Schachter EN. Indacaterol/ glycopyrronium bromide fixed-dose combination for the treatment of COPD. Drugs Today (Barc) 2013;49:437-46 .
9. Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis 2013;7(6):311-19 .
10. Gibb A, Yang LP. Olodaterol: first global approval. Drugs 2013;73:1841-6 .
11. Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in phase I and II clinical trials. Expert Opin Investig Drugs 2012;21:1489-501
12. Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013;14:775-81 .
13. Hughes AD, McNamara A, Steinfeld T. Multivalent dual pharmacology muscarinic antagonist and beta2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem 2012;51:71-95
14. D?Urzo A, Kerwin E, Overend T, et al. Once-daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin 2013. [Epub ahead of print] .
15. Bateman ED, Kornmann O, Ambery C, Norris V. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther 2013;26:581-7.